Palvella Therapeutics (PVLA) Net Cash Flow (2016 - 2026)
Palvella Therapeutics has reported Net Cash Flow over the past 10 years, most recently at -$11.7 million for Q4 2022.
- Quarterly Net Cash Flow fell 83.76% to -$11.7 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$74.0 million through Dec 2022, down 246.39% year-over-year, with the annual reading at -$25.7 million for FY2025, 133.66% down from the prior year.
- Net Cash Flow was -$11.7 million for Q4 2022 at Palvella Therapeutics, down from -$3.0 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $71.2 million in Q1 2018 and troughed at -$57.7 million in Q2 2018.
- The 5-year median for Net Cash Flow is -$3.4 million (2020), against an average of $405100.0.
- Year-over-year, Net Cash Flow surged 1488.58% in 2021 and then plummeted 1235.75% in 2022.
- A 5-year view of Net Cash Flow shows it stood at -$14.3 million in 2018, then surged by 210.81% to $15.8 million in 2019, then crashed by 90.46% to $1.5 million in 2020, then plummeted by 523.13% to -$6.4 million in 2021, then plummeted by 83.76% to -$11.7 million in 2022.
- Per Business Quant, the three most recent readings for PVLA's Net Cash Flow are -$11.7 million (Q4 2022), -$3.0 million (Q3 2022), and -$26.2 million (Q2 2022).